All news

Created in June 2010, this new R&D company for dental solutions, assisted by Atlanpole, raises 400 000 Euros to private investors. At the end of 2011, Dental-Moving launched Easy Macro View (EMV), the first intra-buccal endoscope equipped with a sensor with a diameter of only 3,4 millimeters. Bringing real clinical help and comfort to the dental practitioners, EMV is used at a distance of only 12 mm from the area to treat and thus enables the practitioners to look very closely the pathology which is to be treated.

In-Cell-Art, a company member of Atlanpole Biotherapies, is involved in a collaborative project called EMER IT. This project will apply In-Cell-Art’s nanocarrier technologies to the development of specific polyclonal immunoglobulins [F(ab’)2] against life-threatening pathogens such as Ebola, Nipah, or Avian Flu H5N1. This consortium will also develop and validate DNA vaccines formulated with In-Cell-Art’s nanocarriers against an equine infection. These projects will lead to the proof of concept about the new applications of In-Cell-Art’s nanocarrier technologies for immunization against life-threatening pathogens, safe immunogen production, and horse vaccination.

On March 7th & 8th this year, Atlanpole, Atlanpole Biotherapies and the French LES (Licensing Executive Society) organized a training session in licensing for innovative companies. Report.